PURPOSE: To determine disease-specific survival (DSS) and associated predictive factors after prostate brachytherapy. METHODS AND MATERIALS: A total of 1561 patients underwent brachytherapy for prostate cancer from 1990 to 2004 (median follow-up, 3.8 years). Treatment included brachytherapy alone (n = 634), brachytherapy and hormonal therapy (n = 420), and implant and external beam therapy (n = 507). RESULTS: The DSS and overall survival rates at 10 years were 96% and 74%, respectively. Gleason score significantly impacted DSS, with 10-year rates of 98%, 91%, and 92% for scores of < or = 6, 7, and > or = 8, respectively (p < 0.0001). Multivariate analysis revealed that PSA status after treatment had the most significant effect on DSS. Ten-year DSS rates were 100%, 52%, and 98%, respectively for patients without PSA failure (n = 1430), failure with a doubling time (DT) < or = 10 months (n = 64), and failure with a DT > 10 months (n = 67), respectively (p < 0.0001). In patients with PSA failure, DSS rates were 30%, 67%, and 98%, for those with DT < or = 6 months, > 6-10 months, and > 10 months, respectively (p < 0.0001). CONCLUSIONS: The 10-year DSS rate supports the efficacy of brachytherapy. Patients dying with disease within 10 years after treatment harbor inherently aggressive cancer with high Gleason scores and short DT.
PURPOSE: To determine disease-specific survival (DSS) and associated predictive factors after prostate brachytherapy. METHODS AND MATERIALS: A total of 1561 patients underwent brachytherapy for prostate cancer from 1990 to 2004 (median follow-up, 3.8 years). Treatment included brachytherapy alone (n = 634), brachytherapy and hormonal therapy (n = 420), and implant and external beam therapy (n = 507). RESULTS: The DSS and overall survival rates at 10 years were 96% and 74%, respectively. Gleason score significantly impacted DSS, with 10-year rates of 98%, 91%, and 92% for scores of < or = 6, 7, and > or = 8, respectively (p < 0.0001). Multivariate analysis revealed that PSA status after treatment had the most significant effect on DSS. Ten-year DSS rates were 100%, 52%, and 98%, respectively for patients without PSA failure (n = 1430), failure with a doubling time (DT) < or = 10 months (n = 64), and failure with a DT > 10 months (n = 67), respectively (p < 0.0001). In patients with PSA failure, DSS rates were 30%, 67%, and 98%, for those with DT < or = 6 months, > 6-10 months, and > 10 months, respectively (p < 0.0001). CONCLUSIONS: The 10-year DSS rate supports the efficacy of brachytherapy. Patients dying with disease within 10 years after treatment harbor inherently aggressive cancer with high Gleason scores and short DT.
Authors: J Taylor Whaley; Lawrence B Levy; David A Swanson; Thomas J Pugh; Rajat J Kudchadker; Teresa L Bruno; Steven J Frank Journal: Int J Radiat Oncol Biol Phys Date: 2012-01-31 Impact factor: 7.038
Authors: Alexandru Patriciu; Doru Petrisor; Michael Muntener; Dumitru Mazilu; Michael Schär; Dan Stoianovici Journal: IEEE Trans Biomed Eng Date: 2007-08 Impact factor: 4.538
Authors: T Shaikh; N G Zaorsky; K Ruth; D Y Chen; R E Greenberg; J Li; K Crawford; E M Horwitz Journal: Brachytherapy Date: 2014-11-07 Impact factor: 2.362
Authors: F Guedea; M Ferrer; J Pera; F Aguiló; A Boladeras; J F Suárez; O Cunillera; F Ferrer; Y Pardo; E Martínez; M Ventura Journal: Clin Transl Oncol Date: 2009-07 Impact factor: 3.405
Authors: Gabriele Cozzi; Gennaro Musi; Roberto Bianchi; Danilo Bottero; Antonio Brescia; Antonio Cioffi; Giovanni Cordima; Maurizio Delor; Ettore Di Trapani; Matteo Ferro; Deliu Victor Matei; Andrea Russo; Francesco Alessandro Mistretta; Ottavio De Cobelli Journal: Ther Adv Urol Date: 2017-10-09
Authors: Hyeli Park; Ja Young Kim; Bo Mi Lee; Sei Kyung Chang; Seung Young Ko; Sung Jun Kim; Dong Soo Park; Hyun Soo Shin Journal: Radiat Oncol J Date: 2011-09-30